FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074350030> ?p ?o ?g. }

• W2074350030 endingPage "922" @default.
• W2074350030 startingPage "911" @default.
• W2074350030 abstract "Despite clinical approval of erlotinib, most advanced lung cancer patients are primary non-responders. Initial responders invariably develop secondary resistance, which can be accounted for by T790M-EGFR mutation in half of the relapses. We show that MET is highly expressed in lung cancer, often concomitantly with epidermal growth factor receptor (EGFR), including H1975 cell line. The erlotinib-resistant lung cancer cell line H1975, which expresses L858R/T790M-EGFR in-cis, was used to test for the effect of MET inhibition using the small molecule inhibitor SU11274. H1975 cells express wild-type MET, without genomic amplification (CNV=1.1). At 2 μ M, SU11274 had significant in vitro pro-apoptotic effect in H1975 cells, 3.9-fold (P=0.0015) higher than erlotinib, but had no effect on the MET and EGFR-negative H520 cells. In vivo, SU11274 also induced significant tumour cytoreduction in H1975 murine xenografts in our bioluminescence molecular imaging assay. Using small-animal microPET/MRI, SU11274 treatment was found to induce an early tumour metabolic response in H1975 tumour xenografts. MET and EGFR pathways were found to exhibit collaborative signalling with receptor cross-activation, which had different patterns between wild type (A549) and L858R/T790M-EGFR (H1975). SU11274 plus erlotinib/CL-387,785 potentiated MET inhibition of downstream cell proliferative survival signalling. Knockdown studies in H1975 cells using siRNA against MET alone, EGFR alone, or both, confirmed the enhanced downstream inhibition with dual MET–EGFR signal path inhibition. Finally, in our time-lapse video-microscopy and in vivo multimodal molecular imaging studies, dual SU11274-erlotinib concurrent treatment effectively inhibited H1975 cells with enhanced abrogation of cytoskeletal functions and complete regression of the xenograft growth. Together, our results suggest that MET-based targeted inhibition using small-molecule MET inhibitor can be a potential treatment strategy for T790M-EGFR-mediated erlotinib-resistant non-small-cell lung cancer. Furthermore, optimised inhibition may be further achieved with MET inhibition in combination with erlotinib or an irreversible EGFR-TKI." @default.
• W2074350030 created "2016-06-24" @default.
• W2074350030 creator A5001432192 @default.
• W2074350030 creator A5009957181 @default.
• W2074350030 creator A5019470085 @default.
• W2074350030 creator A5019506336 @default.
• W2074350030 creator A5022475557 @default.
• W2074350030 creator A5033638130 @default.
• W2074350030 creator A5036587861 @default.
• W2074350030 creator A5038809483 @default.
• W2074350030 creator A5038859205 @default.
• W2074350030 creator A5044620494 @default.
• W2074350030 creator A5055297979 @default.
• W2074350030 creator A5066426572 @default.
• W2074350030 creator A5077135617 @default.
• W2074350030 creator A5080242985 @default.
• W2074350030 creator A5081356537 @default.
• W2074350030 creator A5085124229 @default.
• W2074350030 creator A5086324371 @default.
• W2074350030 date "2008-08-26" @default.
• W2074350030 modified "2023-10-07" @default.
• W2074350030 title "Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer" @default.
• W2074350030 cites W1426393029 @default.
• W2074350030 cites W1967394241 @default.
• W2074350030 cites W1969732147 @default.
• W2074350030 cites W1972514043 @default.
• W2074350030 cites W1978177843 @default.
• W2074350030 cites W1980926309 @default.
• W2074350030 cites W1984852348 @default.
• W2074350030 cites W1995862211 @default.
• W2074350030 cites W1998971866 @default.
• W2074350030 cites W2000707284 @default.
• W2074350030 cites W2002937040 @default.
• W2074350030 cites W2003984225 @default.
• W2074350030 cites W2012537836 @default.
• W2074350030 cites W2013678879 @default.
• W2074350030 cites W2014238399 @default.
• W2074350030 cites W2019573100 @default.
• W2074350030 cites W2020995084 @default.
• W2074350030 cites W2021312892 @default.
• W2074350030 cites W2026775820 @default.
• W2074350030 cites W2037355469 @default.
• W2074350030 cites W2046352484 @default.
• W2074350030 cites W2062021371 @default.
• W2074350030 cites W2062766483 @default.
• W2074350030 cites W2082183475 @default.
• W2074350030 cites W2093613683 @default.
• W2074350030 cites W2096844786 @default.
• W2074350030 cites W2106582614 @default.
• W2074350030 cites W2115046988 @default.
• W2074350030 cites W2116987967 @default.
• W2074350030 cites W2117750856 @default.
• W2074350030 cites W2126004255 @default.
• W2074350030 cites W2129787264 @default.
• W2074350030 cites W2136390065 @default.
• W2074350030 cites W2138297714 @default.
• W2074350030 cites W2138309116 @default.
• W2074350030 cites W2138896702 @default.
• W2074350030 cites W2140062641 @default.
• W2074350030 cites W2148971037 @default.
• W2074350030 cites W2156647409 @default.
• W2074350030 cites W2164042520 @default.
• W2074350030 cites W2169983495 @default.
• W2074350030 doi "https://doi.org/10.1038/sj.bjc.6604559" @default.
• W2074350030 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2538758" @default.
• W2074350030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19238632" @default.
• W2074350030 hasPublicationYear "2008" @default.
• W2074350030 type Work @default.
• W2074350030 sameAs 2074350030 @default.
• W2074350030 citedByCount "158" @default.
• W2074350030 countsByYear W20743500302012 @default.
• W2074350030 countsByYear W20743500302013 @default.
• W2074350030 countsByYear W20743500302014 @default.
• W2074350030 countsByYear W20743500302015 @default.
• W2074350030 countsByYear W20743500302016 @default.
• W2074350030 countsByYear W20743500302017 @default.
• W2074350030 countsByYear W20743500302018 @default.
• W2074350030 countsByYear W20743500302019 @default.
• W2074350030 countsByYear W20743500302020 @default.
• W2074350030 countsByYear W20743500302021 @default.
• W2074350030 countsByYear W20743500302022 @default.
• W2074350030 countsByYear W20743500302023 @default.
• W2074350030 crossrefType "journal-article" @default.
• W2074350030 hasAuthorship W2074350030A5001432192 @default.
• W2074350030 hasAuthorship W2074350030A5009957181 @default.
• W2074350030 hasAuthorship W2074350030A5019470085 @default.
• W2074350030 hasAuthorship W2074350030A5019506336 @default.
• W2074350030 hasAuthorship W2074350030A5022475557 @default.
• W2074350030 hasAuthorship W2074350030A5033638130 @default.
• W2074350030 hasAuthorship W2074350030A5036587861 @default.
• W2074350030 hasAuthorship W2074350030A5038809483 @default.
• W2074350030 hasAuthorship W2074350030A5038859205 @default.
• W2074350030 hasAuthorship W2074350030A5044620494 @default.
• W2074350030 hasAuthorship W2074350030A5055297979 @default.
• W2074350030 hasAuthorship W2074350030A5066426572 @default.
• W2074350030 hasAuthorship W2074350030A5077135617 @default.
• W2074350030 hasAuthorship W2074350030A5080242985 @default.
• W2074350030 hasAuthorship W2074350030A5081356537 @default.

• next